Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Wetzel

Showing results (121-130 of 123) with videos related to

Pageof 13
Sort By:
You have reached the last page of results.This site can display upto 123 results.
Journal of Medicinal Chemistry|December 2, 1999
Design and synthesis of novel alpha(1)(a) adrenoceptor-selective antagonists. 2. Approaches to eliminate opioid agonist metabolites via modification of linker and 4-methoxycarbonyl-4-phenylpiperidine moietyT G Murali Dhar, D Nagarathnam, M R Marzabadi, et al.
Nature Biotechnology|November 4, 2000
A T-cell-selective interleukin 2 mutein exhibits potent antitumor activity and is well tolerated in vivoA B Shanafelt, Y Lin, M C Shanafelt, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 5, 2021
IgE blockade with omalizumab reduces pruritus related to immune checkpoint inhibitors and anti-HER2 therapiesD M Barrios, G S Phillips, A N Geisler, et al.
Pageof 13

Showing results (121-130 of 123) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 123 results.
Journal of Medicinal Chemistry|December 2, 1999
Design and synthesis of novel alpha(1)(a) adrenoceptor-selective antagonists. 2. Approaches to eliminate opioid agonist metabolites via modification of linker and 4-methoxycarbonyl-4-phenylpiperidine moietyT G Murali Dhar, D Nagarathnam, M R Marzabadi, et al.
Nature Biotechnology|November 4, 2000
A T-cell-selective interleukin 2 mutein exhibits potent antitumor activity and is well tolerated in vivoA B Shanafelt, Y Lin, M C Shanafelt, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 5, 2021
IgE blockade with omalizumab reduces pruritus related to immune checkpoint inhibitors and anti-HER2 therapiesD M Barrios, G S Phillips, A N Geisler, et al.
Pageof 13